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Summary
Objective.  —  Provide  guidelines  for  practical  usage  of  botulinum  toxin  type  A  (BoNTA)  for  refrac-
tory  idiopathic  overactive  bladder  management.
Patients  and  methods.  —  Guidelines  using  formalized  consensus  guidelines  method.  These
guidelines  have  been  validated  by  a  group  of  13  experts  quoting  proposals,  subsequently
reviewed by  an  independent  group  of  experts.
Results.  —  In  the  case  of  patients  with  urinary  tract  infection,  it  must  be  treated  and  injec-
tion  postponed.  Before  proposing  an  injection,  it  is  recommended  to  ensure  the  feasibility  and
acceptability  of  self-catheterisation  by  patient.  The  injection  can  be  performed  after  local
anesthesia  of  the  bladder  and  urethra  (lidocaine),  supplemented  where  necessary  by  nitrous
oxide  inhalation  and  sometimes  under  general  anesthesia.  Injection  is  performed  in  the  operat-
ing  room  or  endoscopy  suite.  The  bladder  should  not  be  too  ﬁlled  (increased  risk  of  perforation).
Treatment  should  be  applied  in  10  to  20  injections  of  0.5  to  1  mL  homogeneously  distributed  in
the  bladder  at  a  distance  from  the  urethral  oriﬁces.  It  is  not  recommended  to  leave  a  urinary
catheter  in  place  except  in  cases  of  severe  hematuria.  The  patient  should  be  monitored  until
resumption  of  micturition.  After  the  ﬁrst  injection,  an  appointment  must  be  scheduled  within
3  months  (micturition  diary,  uroﬂowmetry,  measurement  of  residual  urine  and  urine  culture).
Performance  of  self-catheterisation  should  be  questioned  in  the  case  of  a  symptomatic  post-
void  residual  and/or  a  residue  >  200  mL.  A  new  injection  may  be  considered  when  the  clinical
beneﬁt  of  the  previous  injection  diminishes  (between  6  and  9  months).  A  period  of  three  months
must  elapse  between  each  injection.
Conclusions.  —  Implementation  of  these  guidelines  may  promote  best  practice  usage  of  BoNTA
with  optimal  risk/beneﬁt  ratio.
©  2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Objectifs.  —  Déﬁnir  des  recommandations  pour  l’utilisation  pratique  de  la  toxine  botulinique
de type  A  (BoNTA)  dans  l’hyperactivité  vésicale  réfractaire  idiopathique  (HAVRI).
Méthode. —  Élaboration  de  recommandations  de  bonne  pratique  par  consensus  formalisé,
validées par  un  groupe  de  13  experts  puis  par  un  groupe  de  lecture  indépendant.
Résultats.  —  En  cas  d’infection  urinaire,  celle-ci  doit  être  traitée  et  l’injection  reportée.  Avant
l’injection, il  est  recommandé  de  s’assurer  de  la  faisabilité  et  de  l’acceptabilité  de  l’auto-
sondage.  L’injection  peut  être  réalisée  après  une  anesthésie  locale  urétro-vésicale  (lidocaïne),
éventuellement  complétée  par  l’inhalation  de  protoxyde  d’azote  et  parfois  sous  anesthésie
générale.  L’injection  sera  réalisée  au  bloc  opératoire  ou  en  salle  d’endoscopie.  La  vessie  ne
doit  pas  être  trop  remplie  (risque  de  perforation).  Le  traitement  doit  être  appliqué  en  10  à
20  injections  de  0,5  à  1  mL  réparti  de  manière  homogène  dans  la  vessie  en  restant  à  distance
des méats  urétéraux.  Il  n’est  pas  recommandé  de  laisser  en  place  une  sonde  vésicale  sauf
en  cas  d’hématurie  importante.  Le  patient  doit  être  surveillé  jusqu’à  la  reprise  mictionnelle.
Une  note  d’information  sur  les  effets  indésirables  éventuels  doit  lui  être  remise  à  sa  sortie.
Botulinum  toxin  type  A  (BoNTA)  e3
Une  consultation  doit  être  prévue  3  mois  après  la  première  injection  (calendrier  miction-
nel,  débit-métrie,  résidu  post-mictionnel  et  examen  cytobactériologique  des  urines).  Un
résidu  >  200  mL  et/ou  symptomatique  doit  faire  discuter  des  auto-sondages.  Une  nouvelle  injec-
tion  pourra  être  envisagée  lorsque  le  bénéﬁce  clinique  de  la  précédente  s’estompe  (entre  6  et
9  mois).
Conclusions.  —  Le  respect  de  ces  recommandations  devrait  permettre  une  utilisation  optimale
de la  BoNTA.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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®Introduction
Since  the  ﬁrst  time  the  botulinum  toxin  A  was  used,  almost
25 years  ago,  on  the  striated  sphincter  of  the  urethra  to  treat
detrusor-sphincter dyssynergia  [1],  the  use  of  botulinum
toxin has  been  progressively  extended  to  numerous  areas
of urology.
Several major  publications  have  allowed  its  application
in neurogenic  detrusor  overactivity  to  be  validated  [2,3],
and this  toxin  has  now  become  a  component  of  the  ther-
apeutic algorithm  used  in  the  management  of  neurological
bladders [4].
New indications,  such  as  the  non-neurological  refractory
overactive bladder,  have  been  studied  [5].
This  pathology  represents  a  diagnostic  and  therapeutic
challenge. It  is  a  functional  pathology  which  is  non  life-
threatening and  has  no  inﬂuence  on  renal  prognosis,  but
which can  lead  to  profound  changes  in  the  patient’s  qual-
ity of  life.  Currently,  the  therapeutic  methods  used  for  its
treatment do  not  allow  this  condition  to  be  fully  managed.
The  efﬁcacy  of  drug  treatments  is  inconsistent,  and  these
can lead  to  side  effects,  which  hinder  observance  of  the
treatment [6].  Behavioural  therapy  and  rehabilitation  are
also ﬁrst  line  treatments,  whose  efﬁcacy  is  unfortunately
inconsistent. Among  possible  second  line  treatments,  percu-
taneous posterior  tibial  nerve  stimulation  can  be  a  suitable
choice in  terms  of  beneﬁt-risk  ratio  [7].  Sacral  neuromod-
ulation, which  is  more  invasive,  is  a  validated  form  of
treatment. It  calls  for  the  use  of  a  preliminary  effective-
ness test,  prior  to  permanent  implantation.  Good  long-term
results have  been  demonstrated,  although  this  is  an  expen-
sive treatment  and  can  have  undesirable  effects,  sometimes
requiring reoperation.  The  use  of  more  complex  surgical
techniques (enterocystoplasty)  is  currently  rare,  in  the  case
of  non-neurological  detrusor  overactivity,  as  a  consequence
of the  morbidity  and  inconsistent  long-term  outcome  asso-
ciated with  its  use.
Currently, numerous  publications  have  reported  on  the
usefulness and  efﬁcacy  of  BoNTA  for  this  indication  [8—10].
Contrary to  neurological  patients,  treatments  involving  the
intradetrusor injection  of  BoNTA  are  confronted  by  the
difﬁculty of  ensuring  voiding  which  is  reliable,  efﬁcient,
spontaneous, and  non-deleterious  (renal  protection  and  risk
of infection).
Although the  efﬁcacy  and  safety  of  botulinum  toxin  A
have been  validated  by  major  evidence-based  publications
(randomized placebo  control  studies),  practical  information
for its  use  cannot  be  based  on  a  strong  consensus.  More-
over, these  studies  are  often  disparate,  in  terms  of  their
inclusion or  exclusion  criteria  (men  and/or  women,  different
w
h
oeﬁnitions  for  the  clinical  criteria  of  OAB,  presence  or
bsence of  detrusor  overactivity,  different  deﬁnitions  for
he refractory  nature  of  the  symptoms)  and  in  the  injection
echnique (high  dosage  —  200  to  300  IU  —  or  low  dosage  —  100
o 150  IU,  number  of  injections,  injection  sites,  dilution  of
he toxin,  submucosal  or  detrusor  injections).  In  France,
rug marketing  approval  for  BoNTA  is  currently  limited  to
ases of  neurogenic  detrusor  overactivity.  The  encouraging
esults described  in  the  literature  have  led  BoNTA  to  be  used
y expert  centres  in  the  scope  of  a  research  protocol,  as  a
ast resort  therapy  for  non-neurological  bladder  overactiv-
ty. A  request  for  an  extension  of  the  French  drug  marketing
pproval (AMM)  has  been  submitted,  and  an  expert  group  has
repared  a  set  of  recommendations  for  the  use  of  BoNTA,
n order  to  govern  medical  practices  should  this  request  be
ranted.
atients and method
s  a  result  of  the  absence  or  the  inadequacy  of  literature
ith a  high  level  of  evidence,  dealing  speciﬁcally  with  ques-
ions related  to  the  practical  use  of  botulinum  toxin  for
his indication,  it  was  not  possible  to  prepare  good  prac-
ice recommendations  using  the  method  for  clinical  practice
ecommendations (CPR).  It  was  thus  necessary  to  use  the
ethod for  formalised  consensus  recommendations  (FCR).
his method  has  the  advantage  of  identifying  the  degree  of
greement, disagreement,  or  indecision  between  experts,
n several  independently  submitted  propositions.  The  cor-
esponding procedure  was  that  published  in  2010  by  the
rench National  Authority  for  Health  (HAS)  [11].  The  ﬁrst
tep was  to  draft  a  list  of  proposed  recommendations,
ased on  the  critical  analysis  of  a  summary  of  accessible
ibliographic data  and  the  discussion  of  current  practices.
 systematic  review  of  the  literature  was  carried  out  on
ubmed using  the  following  keywords:  ‘‘botulinum  toxin’’
nd ‘‘bladder  overactivity’’,  or  ‘‘idiopathic  detrusor  over-
ctivity’’, or  ‘‘non-neurological’’.  Twenty-ﬁve  papers  were
etained  out  of  a  total  of  417  papers  revealed  by  the  bib-
iographic search,  which  was  limited  to  papers  published  in
nglish or  French.
The  analysis  of  these  papers  was  focussed  on  the  pro-
osed indications,  the  criteria  for  primary  and  secondary
fﬁcacy, the  technical  protocols  used  for  the  injections,  and
he reported  side  effects.  Only  those  publications  dealing
ith onabotulinum  toxin  A  (Botox ) were  retained.
The  rating  and  evaluation  group  comprised  13  members
ailing from  different  specialities  (urology,  gynaecology-
bstetrics, or  physical  and  rehabilitation  medicine),  all  of
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hom  deal  with  the  treatment  of  bladder  overactivity.  These
xperts had  not  participated  in  the  initial  elaboration  of  the
oted proposals.  The  initial  version  of  the  recommendations
as electronically  submitted  for  a  ﬁrst  round  of  ratings.  Each
ember of  the  group  was  required  to  rate  each  proposal
ith a  grade  ranging  from  1  to  9,  with  1  corresponding  to  a
otally inappropriate  proposal,  9  corresponding  to  a  totally
ppropriate proposal,  and  5  corresponding  to  an  undecided
pinion.
Following the  analysis  and  summary  of  the  responses,
he group  met  in  order  to  validate  the  recommendations.
 recommendation  was  accepted  in  the  case  of  strong  group
pproval (median  rating  greater  than  or  equal  to  7,  and  rat-
ngs lying  in  the  range  between  7  and  9).  The  group  was
hen invited  to  provide  details  of  the  reasoning  behind  the
nappropriate and  uncertain  proposals,  and  following  this
iscussion each  member  was  given  the  opportunity  to  modify
is/her rating.
Following this  meeting,  any  modiﬁcations  to  the  propos-
ls, or  the  potential  withdrawal  of  some  proposals,  could  be
ecided upon.
This questionnaire  was  then  submitted  for  a  second  round
f ratings  requiring  a  certain  degree  of  tolerance,  so  that  the
ystematic rejection  of  any  proposals  by  one  expert  could
ot block  the  proposal  selection  process.
The  rating  group  then  met  a  second  time,  in  order  to
stablish a  consensus  of  recommendations,  with  proposals
aving the  option  of  being  classed  as  appropriate,  uncertain
r inappropriate.
An initial  version  of  the  recommendations  was  thus  estab-
ished. This  was  submitted  for  evaluation  to  a  reading  group
omprising 30  participating  urologists,  gynaecologists  and
pecialists in  physical  and  rehabilitation  medicine.  Sixteen
embers (53%)  of  the  reading  group  replied.  These  mem-
ers gave  their  opinion  on  the  content  and  form  of  the
nitial version  of  the  recommendations,  in  particular  con-
erning their  acceptability,  applicability  and  clarity.  An
nalysis and  synthesis  of  these  responses  was  compiled  by
he project  leader,  who  drafted  any  necessary  modiﬁcations.
hese minor  modiﬁcations  concerned  mainly  the  comments
dded to  the  recommendations.  The  ﬁnal  text  was  then
alidated.
esults
ndications and contraindications
 Botox® injection  can  be  used  for  idiopathic  bladder  over-
ctivity which  has  developed  over  a  period  of  at  least  six
onths.
As a  general  rule,  Botox® is  not  a  ﬁrst  line  treatment
or idiopathic  bladder  overactivity,  except  when  there  is  a
ontraindication for  a  ﬁrst  line  pharmacological  treatment.
The  failure  of  an  anticholinergic  treatment  is  deﬁned  by
he absence  of  any  signiﬁcant  efﬁcacy,  with  at  least  two
harmacological agents  taken  orally  at  the  dosage  recom-
ended by  the  French  AMM,  for  a  period  of  three  months,
r by  the  interruption  of  treatment  due  to  adverse  effects.
Botox® injections  are  contraindicated  during  pregnancy,
reastfeeding, in  the  case  of  myasthenia  gravis  or  an  amino-
lycoside treatment.
U
I
tJ.-F.  Hermieu  et  al.
An  evaluation  period  of  at  least  6  months  for  idiopathic
ladder overactivity  was  retained,  in  order  to  be  certain  of
ealing with  the  context  of  a  chronic,  but  not  a  subacute  or
cute pathology.
As a  consequence  of  the  invasive  nature  of  an  intrade-
rusor Botox® injection,  and  the  availability  of  ﬁrst  line
harmacological or  rehabilitative  treatments,  the  botulinum
oxin injection  remains  a  second  line  treatment.
The  criteria  retained  to  determine  the  failure  of  ﬁrst
ine treatments  vary  widely  in  the  literature.  Very  often,
his is  related  to  the  failure  of  one  or  sometimes  several
nticholinergics, or  sometimes  the  failure  of  anticholiner-
ics and  physical  rehabilitation  or  behavioural  methods.  The
ecommendation adopts  the  notion  of  failure  of  at  least  two
rally administered  pharmacological  agents,  in  order  to  test
rugs having  different  availabilities  or  modes  of  action.
In  order  to  account  for  the  practical  constraints  of  consul-
ations, a  period  of  at  least  three  months  of  treatment  was
equired, although  periods  of  one  to  two  months  are  fre-
uently encountered  in  the  literature.
valuation prior to injection
efore  proposing  a  Botox® injection,  conﬁrmation  of  the
diopathic nature  of  an  overactive  bladder  requires  any  pos-
ible urological,  gynaecological,  neurological  or  psychogenic
ause to  be  eliminated  by  means  of  a full  clinical  assess-
ent, uroﬂowmetry  evaluation,  cytobacteriological  testing
f the  urine,  and  ultrasound  imagery  of  the  urinary  tract
ombined with  a  measurement  of  the  post-void  residual  and
ndoscopy of  the  bladder.
It  is  recommended  to  establish  a voiding  diary  before
nitiating a treatment  involving  Botox® injections.
Full  exploration  of  the  bladder-sphincter  function  by
eans of  a  urodynamic  evaluation,  including  exploration
f the  voiding  phase,  is  recommended  prior  to  carrying  out
otox® injections.
The  search  for  the  cause  of  bladder  overactivity  is
n indispensable  prerequisite.  Indeed,  the  discovery  of  a
ro-gynaecological or  neuro-psychogenic  aetiology  requires
rior treatment  of  the  cause,  before  envisaging  any  possible
ymptomatic treatment.
The  purpose  of  a  voiding  calendar  is  to  determine  the
requency and  volume  of  daytime  and  night-time  urination,
he number  of  episodes  of  urge  incontinence  with  or  without
eakage, and  the  daily  volume  of  urine.
Concerning  the  role  of  a  urodynamic  evaluation  prior
o making  intradetrusor  injections  of  Botox®,  no  consensus
as reached.  Most  experts  recommended  its  systematic  use.
ome experts  preferred  to  limit  exploration  of  the  bladder-
phincter function  to  a urodynamic  evaluation,  including
xploration of  the  voiding  stage  in  at-risk  patients  (sub-
ects over  65  years  in  age,  males,  with  a history  of  pelvic
urgery or  sacral  neuromodulation  failure,  mixed  urinary
ncontinence, ﬂowmeter  abnormalities,  or  the  presence  of
 signiﬁcant  post-voiding  residual).rinary tract infection and antibioprophylaxis
n  the  case  of  a positive  cytobacteriological  examination  of
he urine,  a  Botox® injection  should  not  be  carried  out.  In
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the  case  of  a  urinary  tract  infection,  this  must  be  treated
and the  injection  postponed.
Current  knowledge  does  not  allow  any  conclusion  to  be
made concerning  the  usefulness  of  an  antibioprophylaxis
carried out  prior  to  a  Botox® injection.  In  a  neurological
patient, the  legal  terms  of  use  recommend  the  administra-
tion of  an  antibiotic  for  1  to  3  days  prior  to  treatment  (at
least two  days  in  the  case  of  asymptomatic  bacterial  coloni-
sation), on  the  day  of  treatment,  and  1  to  3  days  following
treatment (at  least  two  days  in  the  case  of  asymptomatic
bacterial colonisation).  These  recommendations  cannot  be
extended to  the  case  of  non-neurological  patients,  who  have
quite different  bacteriological  urine  proﬁles.
In  published  studies,  injection  protocols  have,  or  have
not included  an  antibioprophylactic  treatment  (with  differ-
ing product,  dosage  and  duration  modalities).  Although  the
rate of  urinary  tract  infections  appears  to  be  signiﬁcantly
higher, following  a  Botox® injection,  than  in  the  case  of
a placebo,  this  appears  to  be  more  closely  related  to  the
Botox® injection  dosage,  to  the  existence  of  a  post-voiding
residual, or  to  the  absence  of  a  clear  deﬁnition  of  a  uri-
nary tract  infection  in  the  studies,  than  to  the  use  of,  or  the
modalities of  the  antibioprophylaxis.  However,  until  now  no
study has  provided  a  speciﬁc  response  to  this  question.
Anticoagulants and antiplatelet drugs
It  is  not  recommended  to  make  a  Botox® injection  in  a
patient treated  with  oral  anticoagulants.
The  approach  to  be  taken  with  respect  to  antiplatelet
agents is  deﬁned  by  the  good  practice  recommendation  of
the French  National  Authority  for  Health  (HAS),  related  to
the importance  of  taking  thrombotic  and  haemorrhagic  risks
into account  during  a  urological  endoscopic  procedure  in  a
coronary patient  (June  2012)  [12].
It  is  always  advisable  to  compare  the  thrombotic  risk
associated with  the  withdrawal  or  modiﬁcation  of  an
antiplatelet treatment,  with  the  haemorrhagic  risk  associ-
ated with  the  injection.
The haemorrhagic  risk  with  a  Botox® injection  can  be
likened to  that  of  a  bladder  biopsy.
In  the  case  of  a  major  thrombotic  risk,  it  is  recommended
to delay  the  procedure,  or  to  maintain  the  treatment
using acetylsalicylic  acid  and  to  stop  the  administration  of
clopidogrel 5  days  beforehand  (or  of  prasugrel  7 days  before-
hand).
In the  case  of  a  minor  thrombotic  risk,  when  acetylsali-
cylic acid  monotherapy  is  used,  this  must  be  stopped  3  days
beforehand.
In the  case  of  a  clopidrogrel  monotherapy,  this  is  to  be
stopped 5  days  beforehand  or  possibly  replaced  by  acetyl-
salicylic acid.
In the  absence  of  any  active  bleeding,  resumption  of  an
antiplatelet agent  treatment  must  be  initiated  as  soon  as
possible, if  possible  the  same  day  as  the  injection.
Feasibility and acceptance of
self-catheterisationBefore  proposing  a  Botox® injection,  it  is  recom-
mended to  verify  the  feasibility  and  acceptability  of
self-catheterisation.
[
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According  to  major  evidence-based  study  publications,
he rate  at  which  self-catheterisation  is  adopted,  follow-
ng an  intradetrusor  injection  of  Botox®, decreases  with  the
njected dose,  leading  to  self-catheterisation  rates  greater
han 40%  at  300  units  (Botox®),  of  the  order  of  30%  at
00 units  (Botox®),  and  lying  in  the  range  between  7%  and
1% at  100  units  (Botox®) [2,9,13].
These ﬁndings  make  it  necessary  to  correctly  inform  the
reated patients,  to  conﬁrm  the  acceptability  of  this  risk  and
o verify  their  ability  to  implement  this  gesture.  A  pp-test
an be  used  to  verify  the  patient’s  aptitude  [14].
The  recommended  dose  is  that  having  the  best  beneﬁt-
isk ratio,  i.e.  100  units  (Botox®).
naesthetic procedures
he  Botox® injection  can  be  carried  out  following  local
rethrovesical anaesthesia  using  lidocaine,  possibly  supple-
ented by  the  inhalation  of  nitrous  oxide.
This  involves  instilling  a  solution  of  two  vials  of  2%
idocaine without  adrenaline  in  30  mL  of  14  per  1000  bicar-
onate, supplemented  by  the  instillation  of  one  vial  of
idocaine gel  in  the  urethra.
The  injection  of  Botox® can  sometimes  be  carried  out
nder general  anaesthesia,  depending  on  the  patient’s  pain
erception threshold.
Most  published  studies  make  use  of  local  anaesthesia
nvolving, at  varying  degrees,  intravesical  and  intraurethral
idocaine, sometimes  associated  with  sedation.  Some  pro-
ocols make  use  of  general  anaesthesia,  which  is  however
ifﬁcult to  accept  for  this  functional  pathology,  when  low
ain perception  thresholds  have  been  reported  under  local
naesthesia.
ractical methods for carrying out injections
mmediately  prior  to  making  a  Botox® injection,  it  is  rec-
mmended to  carry  out  an  endoscopic  exploration  of  the
ladder, to  verify  its  normality.
The  injection  is  carried  out  in  an  operating  room  or  an
ndoscopy room  by  a  practitioner  trained  in  this  technique,
sing a  rigid  or  a  ﬂexible  cystoscope,  whilst  respecting  the
sual aseptic  precautions.
The  recommended  irrigation  ﬂuid  is  an  isotonic  solution
f sodium  chloride.
The  needle  must  be  suitable  for  this  application.
The bladder  must  not  be  too  full,  at  the  risk  of  making
ts lining  thinner,  leading  to  perforation.
The  needle  must  penetrate  the  detrusor,  without  trans-
xing it.
The treatment  must  be  applied  using  at  least  10  to  20
njections of  0.5  to  1  mL,  which  are  uniformly  distributed
ver the  bladder,  whilst  remaining  at  a  good  distance  from
he urethral  meatus.
The  last  injection  must  be  made  with  0.5  or  1  mL  of
hysiological saline,  to  ensure  that  the  foreseen  dose  is
orrectly delivered,  despite  the  dead  space  of  the  needle.
he injection  protocols  used  in  the  main  published  studies
8—10,13,15—20] report  the  use  of  0.5  to  1  mL  unit  injections
ontaining 5  to  10  units  of  botulinum  toxin  (Botox®).
It is  not  recommended  to  leave  a  urinary  catheter  in
lace, except  in  the  case  of  major  hematuria.
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Studies  comparing  submucosal  and  intradetrusor  injec-
ions do  not  appear  to  show  any  signiﬁcant  differences,  even
hough this  distinction  appears  rather  artiﬁcial  [21,22].  In
act, there  is  no  accurate  method  for  controlling  the  depth
f injection,  since  this  depends  on  the  thickness  of  the  blad-
er wall,  the  extent  of  its  ﬁbrosis,  the  degree  of  bladder
lling, the  type  of  needle  used,  and  the  pressure  applied  by
he operator.
Injections in  the  region  of  the  trigone  do  not  appear
o induce  any  vesicoureteral  reﬂux.  However,  they  do  not
ppear to  be  efﬁcient,  nor  to  induce  less  post-operative
esidual, than  injections  uniformly  distributed  over  the
obile part  of  the  bladder  [23,24].
recautions for use
s  soon  as  it  has  been  prepared  in  the  needle,  the  solution
ust be  used  immediately.
Disposable equipment  must  be  stored  in  appropriate  con-
ainers prior  to  incineration.
Surfaces contaminated  by  the  botulinum  toxin  solution
ust be  cleaned  with  an  absorbent  cloth  soaked  in  a  sodium
ypochlorite solution  (bleach).
In  the  case  of  an  accidental  projection  into  the  eye,  it  is
ecommended to  rinse  the  eye  abundantly  with  water.
In  the  case  of  accidental  projection  onto  the  skin,  it  is
ecommended to  apply  a  sodium  hypochlorite  solution,  fol-
owed  by  abundant  rinsing  with  water.
ost-operative follow-up
he  patient  must  be  monitored  until  urinary  recovery.  An
nformation leaﬂet  must  be  handed  to  the  patient  after  the
njection, and  this  must  in  particular  indicate  that  in  the
ase of  burning  micturition,  fever,  difﬁculties  with  urination,
r an  abundance  of  blood  in  the  urine,  the  patient  must
onsult without  delay.
After the  ﬁrst  injection,  a  consultation  must  be  foreseen
ithin a  period  of  three  months  following  the  injection,  in
rder to  evaluate  the  treatment’s  efﬁcacy.  This  evaluation
ust include  a  urinary  diary,  ﬂowmeter  analysis,  a  measure-
ent of  the  post-void  residual,  and  a  cytobacteriological
xamination  of  the  patient’s  urine.
A  post-void  residual  which  is  greater  than  200  mL  and/or
ymptomatic must  be  accompanied  by  discussion  of  the  use
f  self-catheterisation.
A renewed  injection  can  be  envisaged  when  the  clinical
eneﬁt of  the  preceding  injection  wears  off  (typically  after
 period  of  6 to  9  months).
In all  cases,  a  delay  of  three  months  must  be  respected
etween each  injection.
A delay  of  two  weeks  is  indicated  by  major  evidence-
ased studies,  until  maximum  efﬁcacy  is  achieved.
A  decision  to  initiate  self-catheterisation  should  take
omplete analysis  of  the  clinical  situation,  together  with  the
oiding catalogue  and  ﬂowmeter  analysis,  into  account.
Apart  from  the  absolute  value  of  the  post-void  residual,
he ratio  between  the  residual  and  the  bladder  capacity,  the
ossible need  for  abdominal  thrust,  and  the  clinical  toler-
nce expressed  by  the  patient  must  be  taken  into  account.
In  the  case  of  a  lack  of  efﬁcacy  following  injection,  a
0 unit  stepwise  increase  in  BoNTA  (Botox®)  dosage  canJ.-F.  Hermieu  et  al.
e  envisaged,  by  evaluating  the  beneﬁt-risk  ratio  for  the
atient.
The notion  of  dosage  adjustment  during  injection  is  based
n data  found  in  the  literature.  Dowson  et  al.  propose  an
ncrease in  dosage  in  the  case  of  insufﬁcient  efﬁcacy,  and
 reduction  in  dosage  in  the  case  of  a  signiﬁcant  residual
olume [25].
onclusion
he  literature  provides  data  with  a  high  level  of  evi-
ence in  terms  of  the  efﬁcacy/tolerance  proﬁle  of  the
otulinum toxin  A  (onabotulinum  toxin  A/Botox®),  allow-
ng the  botulinum  toxin  to  be  included  in  the  therapeutic
lgorithm for  the  refractory  idiopathic  overactive  bladder.
These  recommendations  provide  a  summary  of  current
ata found  in  the  literature  and  expert  practice  concerning
ts methods  of  use.
Their  aim  is  to  harmonise  practices,  to  assist  the  practi-
ioner with  his/her  therapeutic  options,  to  guide  diagnostic
valuations and  the  treatment  and  monitoring  of  patients,
nd to  limit  the  risks  associated  with  incorrect  usage  of  this
edication.
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